세계의 액체생검 시장 규모 조사 및 예측 : 제품 및 서비스별, 순환 바이오마커별, 암 유형별, 최종사용자별, 지역별 분석(2023-2030년)

Global Liquid Biopsy Market is valued at approximately USD 4.30 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 18.50% over the forecast period 2023-2030. The global liquid biopsy market refers to the market for diagnostic tests that detect cancer and other diseases by analyzing genetic material or biomarkers in bodily fluids such as blood, urine, and cerebrospinal fluid. Liquid biopsy tests are non-invasive and provide a less expensive and less risky alternative to traditional tissue biopsies, which involve the removal of tissue samples from the body. The major driving factors for the Global Liquid Biopsy Market are the increasing prevalence of cancer and the growing demand for non-invasive diagnostic tests. Moreover, rising technological advancements and increasing investment in research and development are creating lucrative growth opportunities for the market over the forecast period 2023-2030.

Companies and research institutions are investing heavily in research and development to improve the sensitivity, specificity, and accuracy of liquid biopsy tests, which is driving innovation in the field. For instance, in 2020, Guardant Health invested USD 100 million in a new research and development facility focused on liquid biopsy technology. The company has also announced plans to develop new liquid biopsy tests for use in cancer diagnosis and treatment. Similarly, Grail, a leading liquid biopsy company, has raised over USD 6 billion in funding since 2020, with a significant portion of this investment dedicated to research and development. The company has developed a multi-cancer early-detection test and is currently conducting clinical trials to validate its efficacy. However, the high cost of Liquid Biopsy stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Liquid Biopsy Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is the largest market for liquid biopsy, driven by the presence of several key players in the region, as well as a favorable regulatory environment for the development and commercialization of new technologies. The United States is the biggest contributor to the growth of the North American liquid biopsy market. Asia Pacific is a rapidly growing market for liquid biopsy, driven by the increasing prevalence of cancer in the region and a growing focus on personalized medicine. Countries such as China, Japan, and India are expected to be major contributors to the growth of the Asia Pacific liquid biopsy market.

Major market players included in this report are:

• Guardant Health
• Grail
• Illumina, Inc
• Freenome
• Biocept, Inc
• Natera, Inc.
• Cardiff OncologyRainDance Technologies
• Adaptive Biotechnologies
• Exosome Diagnostics, Inc.

Recent Developments in the Market:

• In November 2021, Grail announced the launch of its large-scale clinical trial, the Circulating Cell-Free Genome Atlas (CCGA) study, which aims to validate the effectiveness of its liquid biopsy technology for the early detection of cancer.
• In August 2020, Guardant Health announced the launch of its liquid biopsy test, Guardant360 CDx, which can detect multiple cancer biomarkers in a single blood sample.

Global Liquid Biopsy Market Report Scope:

• Historical Data: - 2020 - 2021
• Base Year for Estimation: - 2022
• Forecast period: - 2023-2030
• Report Coverage: - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: - Product and Services, Circulating Biomarker, Cancer Type, End-user, Region
• Regional Scope: - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Product and Services offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Product and Services:

• Kits & Reagents
• Platforms & Instruments
• Services

By Circulating Biomarker:

• Circulating Tumor Cells
• Extracellular Vesicles
• Circulating Tumor DNA [ctDNA]
• Other Biomarkers

By Cancer Type:

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Other Cancers  

By End-user:

• Hospitals & Laboratories
• Government & Academic Research Centers

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Liquid Biopsy Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Liquid Biopsy Market, by Product and Services, 2020-2030 (USD Billion)
  • 1.2.3. Liquid Biopsy Market, by Circulating Biomarker, 2020-2030 (USD Billion)
  • 1.2.4. Liquid Biopsy Market, by Cancer Type, 2020-2030 (USD Billion)
  • 1.2.5. Liquid Biopsy Market, by End-user, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Liquid Biopsy Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Liquid Biopsy Market Dynamics

• 3.1. Liquid Biopsy Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing prevalence of cancer
    • 3.1.1.2. Growing demand for non-invasive diagnostic tests
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Cost of Liquid Biopsy
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Advancements in Formulation
    • 3.1.3.2. Rising initiatives by key market players

Chapter 4. Global Liquid Biopsy Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Liquid Biopsy Market, by Product and Services

• 5.1. Market Snapshot
• 5.2. Global Liquid Biopsy Market by Product and Services, Performance - Potential Analysis
• 5.3. Global Liquid Biopsy Market Estimates & Forecasts by Product and Services 2020-2030 (USD Billion)
• 5.4. Liquid Biopsy Market, Sub Segment Analysis
  • 5.4.1. Kits & Reagents
  • 5.4.2. Platforms & Instruments
  • 5.4.3. Services

Chapter 6. Global Liquid Biopsy Market, by Circulating Biomarker

• 6.1. Market Snapshot
• 6.2. Global Liquid Biopsy Market by Circulating Biomarker, Performance - Potential Analysis
• 6.3. Global Liquid Biopsy Market Estimates & Forecasts by Circulating Biomarker 2020-2030 (USD Billion)
• 6.4. Liquid Biopsy Market, Sub Segment Analysis
  • 6.4.1. Circulating Tumor Cells
  • 6.4.2. Extracellular Vesicles
  • 6.4.3. Circulating Tumor DNA [ctDNA]
  • 6.4.4. Other Biomarkers

Chapter 7. Global Liquid Biopsy Market, by Cancer Type

• 7.1. Market Snapshot
• 7.2. Global Liquid Biopsy Market by Cancer Type, Performance - Potential Analysis
• 7.3. Global Liquid Biopsy Market Estimates & Forecasts by Cancer Type 2020-2030 (USD Billion)
• 7.4. Liquid Biopsy Market, Sub Segment Analysis
  • 7.4.1. Lung Cancer
  • 7.4.2. Breast Cancer
  • 7.4.3. Colorectal Cancer
  • 7.4.4. Prostate Cancer
  • 7.4.5. Liver Cancer
  • 7.4.6. Other Cancers  

Chapter 8. Global Liquid Biopsy Market, by End-user

• 8.1. Market Snapshot
• 8.2. Global Liquid Biopsy Market by End-user, Performance - Potential Analysis
• 8.3. Global Liquid Biopsy Market Estimates & Forecasts by End-user 2020-2030 (USD Billion)
• 8.4. Liquid Biopsy Market, Sub Segment Analysis
  • 8.4.1. Hospitals & Laboratories
  • 8.4.2. Government & Academic Research Centers

Chapter 9. Global Liquid Biopsy Market, Regional Analysis

• 9.1. Top Leading Countries
• 9.2. Top Emerging Countries
• 9.3. Liquid Biopsy Market, Regional Market Snapshot
• 9.4. North America Liquid Biopsy Market
  • 9.4.1. U.S. Liquid Biopsy Market
    • 9.4.1.1. Product and Services breakdown estimates & forecasts, 2020-2030
    • 9.4.1.2. Circulating Biomarker breakdown estimates & forecasts, 2020-2030
    • 9.4.1.3. Cancer Type breakdown estimates & forecasts, 2020-2030
    • 9.4.1.4. End-user breakdown estimates & forecasts, 2020-2030
  • 9.4.2. Canada Liquid Biopsy Market
• 9.5. Europe Liquid Biopsy Market Snapshot
  • 9.5.1. U.K. Liquid Biopsy Market
  • 9.5.2. Germany Liquid Biopsy Market
  • 9.5.3. France Liquid Biopsy Market
  • 9.5.4. Spain Liquid Biopsy Market
  • 9.5.5. Italy Liquid Biopsy Market
  • 9.5.6. Rest of Europe Liquid Biopsy Market
• 9.6. Asia-Pacific Liquid Biopsy Market Snapshot
  • 9.6.1. China Liquid Biopsy Market
  • 9.6.2. India Liquid Biopsy Market
  • 9.6.3. Japan Liquid Biopsy Market
  • 9.6.4. Australia Liquid Biopsy Market
  • 9.6.5. South Korea Liquid Biopsy Market
  • 9.6.6. Rest of Asia Pacific Liquid Biopsy Market
• 9.7. Latin America Liquid Biopsy Market Snapshot
  • 9.7.1. Brazil Liquid Biopsy Market
  • 9.7.2. Mexico Liquid Biopsy Market
• 9.8. Middle East & Africa Liquid Biopsy Market
  • 9.8.1. Saudi Arabia Liquid Biopsy Market
  • 9.8.2. South Africa Liquid Biopsy Market
  • 9.8.3. Rest of Middle East & Africa Liquid Biopsy Market

Chapter 10. Competitive Intelligence

• 10.1. Key Company SWOT Analysis
  • 10.1.1. Company 1
  • 10.1.2. Company 2
  • 10.1.3. Company 3
• 10.2. Top Market Strategies
• 10.3. Company Profiles
  • 10.3.1. Guardant Health
    • 10.3.1.1. Key Information
    • 10.3.1.2. Overview
    • 10.3.1.3. Financial (Subject to Data Availability)
    • 10.3.1.4. Product Summary
    • 10.3.1.5. Recent Developments
  • 10.3.2. Grail
  • 10.3.3. Illumina , Inc
  • 10.3.4. Freenome
  • 10.3.5. Biocept , Inc
  • 10.3.6. Natera , Inc.
  • 10.3.7. Cardiff OncologyTrovagene
  • 10.3.8. RainDance Technologies
  • 10.3.9. Adaptive Biotechnologies
  • 10.3.10. Exosome Diagnostics , Inc.

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes
• 11.3. Research Assumption